Severe toxicity, but long-term persistence of CAR T cells after immune checkpoint inhibitors in large B-cell lymphoma

Leuk Lymphoma. 2024 Nov 20:1-6. doi: 10.1080/10428194.2024.2430703. Online ahead of print.

Xavier Deschênes-Simard^{1

2}, Martina Pennisi³, Miguel-Angel Perales^{4

5}, Gunjan L Shah^{4

5}, Andrew D Zelenetz^{5

6}, Joachim Yahalome G, Brandon S Imber^{5

7

8}, Bianca D Santomasso^{5

9

10}, Parastoo B Dahi^{4

5}

¹ Cellular Therapy Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
² Department of Medicine, University of Montreal, Montréal, Quebec, Canada.
³ Department of Hematology, Fondazione IRCCS Istituto Nazionale deiTumori, Milan, Italy.
⁴ Adult Bone Marrow Transplant Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
⁵ Department of Medicine, Weill Cornell Medical College, New York, NY, USA.
⁶ Lymphoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
⁷ Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
⁸ Early Drug Development Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
⁹ Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
¹⁰ Brain Tumor Center, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

No abstract available